Natalizumab: increased vigilance is required in treating patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2008, v. 1, n. 3, p. 155, doi. 10.1177/1756285608099125
- By:
- Publication type:
- Article
Works matching IS 17562856 AND DT 2008 AND VI 1 AND IP 3
Results: 7
1
2
Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2008, v. 1, n. 3, p. 151, doi. 10.1177/1756285608099124
- By:
- Publication type:
- Article
3
Acknowledgements.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2008, v. 1, n. 3, p. 207, doi. 10.1177/1756285608099023
- Publication type:
- Article
4
Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2008, v. 1, n. 3, p. 193, doi. 10.1177/1756285608098422
- By:
- Publication type:
- Article
5
Review: Escalating immunotherapy of multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2008, v. 1, n. 3, p. 181, doi. 10.1177/1756285608098359
- By:
- Publication type:
- Article
6
Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood—brain barrier.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2008, v. 1, n. 3, p. 167, doi. 10.1177/1756285608097775
- By:
- Publication type:
- Article
7
Review: Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2008, v. 1, n. 3, p. 157, doi. 10.1177/1756285608097463
- By:
- Publication type:
- Article